In light of the available data on IL17A-blocking in the pathogenesis of atherosclerosis and cardiovascular disease, it will be important to confirm the present observations in independent future studies and, depending on the findings in subsequent studies, consider whether it would be prudent to explore further the clinically used human-specific only affibody molecule ABY-035 as a potential therapeutic agent in blocking IL17A in subjects with atherosclerosis. The gene discussed is IL17A; the disease is atherosclerosis.